other material
confidence high
sentiment neutral
materiality 0.35
Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial
Cyclerion Therapeutics, Inc.
- Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.
- Under license amendment, Cyclerion is owed $1.0M upon first patient dosed in a US Phase 2 trial.
- The milestone payment is not yet due as dosing has not begun.